RxDoctor Payments Data

Jeffrey Friedman, MD

Physical Medicine & Rehabilitation · Paoli, PANPI 1184739500

Payments from drug & device makers

$1,383in general payments, 2019–2025

Across 68 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mentor Worldwide LLC$374
  • Supernus Pharmaceuticals, Inc.$371
  • AbbVie$222
  • SPR Therapeutics, Inc$123
  • Merz Pharmaceuticals, LLC$93
  • Biodelivery Sciences International, Inc.$53
  • plus $148 from 9 others

What the payments were for

  • Food & beverage$1,383100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,383 in reported general payments places this provider in the 80th percentile of 550 physical medicine & rehabilitation providers in Pennsylvania.

See all physical medicine & rehabilitation providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$704,860
Medicare patients
611
Services billed
48,926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina25$44,248
OxycontinOxycodone Hcl19$12,763
Oxycodone Hcl273$4,493
Gabapentin322$4,153
Duloxetine Hcl89$3,014
Fentanyl24$2,456
Buprenorphine15$2,435
Baclofen147$2,338
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen99$1,890
Pregabalin76$1,877
Morphine Sulfate ErMorphine Sulfate68$1,493
Metaxalone13$1,427
Lidocaine15$1,248
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl13$1,064
Morphine Sulfate45$951

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$222$44,24825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 550 physical medicine & rehabilitation providers in Pennsylvania.

Other physical medicine & rehabilitation in Paoli

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →